Windtree Therapeutics (WINT) News Today $8.29 +5.00 (+151.98%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 27 at 5:06 AM | benzinga.comWindtree Therapeutics (NASDAQ:WINT) Stock, Short Interest ReportJuly 27 at 5:06 AM | msn.comWhat's Going On With Windtree Therapeutics Stock?July 27 at 5:06 AM | msn.comWindtree Therapeutics Advances Heart Failure Treatment in New Clinical TrialsJuly 26 at 8:01 AM | investorplace.comWhy Is Windtree Therapeutics (WINT) Stock Up 116% Today?July 25 at 11:30 PM | marketwatch.comWindtree Therapeutics Up 61% After Hours on Withdrawn Equity OfferingJuly 25 at 8:36 AM | finance.yahoo.comWindtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial DataJuly 25 at 8:00 AM | globenewswire.comWindtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial DataJuly 24 at 12:53 AM | bizjournals.comCash-strapped Windtree Therapeutics closes $12.9M financing dealJuly 23, 2024 | stockhouse.comWindtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred StockMay 9, 2024 | msn.comWindtree Therapeutics Regains Nasdaq Compliance with Minimum Bid Price RequirementMay 7, 2024 | finance.yahoo.comWindtree Therapeutics Regains Compliance with NasdaqMay 7, 2024 | marketbeat.comTrading was temporarily halted for "WINT" at 10:05 AM with a stated reason of "LULD pause."May 4, 2024 | morningstar.comWindtree Therapeutics Inc WINTApril 22, 2024 | bizjournals.comWindtree Therapeutics is dangerously low on cashApril 22, 2024 | marketbeat.comTrading was temporarily halted for "WINT" at 07:04 PM with a stated reason of "News pending."April 21, 2024 | msn.comWindtree Therapeutics Announces Reverse Stock Split in Strategy to Boost Market ComplianceApril 18, 2024 | msn.comWhy Windtree Therapeutics (WINT) Stock Is Getting HammeredApril 18, 2024 | globenewswire.comWindtree Therapeutics Announces Reverse Stock SplitApril 17, 2024 | finance.yahoo.comWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesApril 17, 2024 | globenewswire.comWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesApril 9, 2024 | finanznachrichten.deWindtree Therapeutics: Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingApril 8, 2024 | globenewswire.comWindtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingFebruary 2, 2024 | msn.comWindtree Therapeutics Seeks Strategic Alternatives with Ladenburg ThalmannFebruary 1, 2024 | finance.yahoo.comWindtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a ResearchJanuary 31, 2024 | bizjournals.comWindtree Therapeutics hires investment bank to explore M&A optionsJanuary 31, 2024 | finance.yahoo.comWindtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesJanuary 29, 2024 | benzinga.comWindtree Therapeutics – This Biotech Inks License Deal For Lead CandidateJanuary 26, 2024 | finanznachrichten.deWindtree Therapeutics Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 26, 2024 | finance.yahoo.comWindtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 25, 2024 | benzinga.comWindtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 25, 2024 | finance.yahoo.comWindtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyJanuary 24, 2024 | money.usnews.comWindtree Therapeutics IncJanuary 18, 2024 | msn.comWindtree and Lee’s sign licence deal for heart failure therapyJanuary 18, 2024 | finance.yahoo.comUp To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater ChinaJanuary 17, 2024 | bizjournals.comWindtree Therapeutics signs drug licensing deal valued at up to $138M with Chinese drug companyJanuary 17, 2024 | finance.yahoo.comWindtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific RegionJanuary 4, 2024 | markets.businessinsider.comHold Rating on Windtree Therapeutics Pending Key Istaroxime StudiesJanuary 3, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Windtree Therapeutics (WINT) with Neutral RecommendationJanuary 2, 2024 | markets.businessinsider.comWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorJanuary 2, 2024 | finance.yahoo.comWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorDecember 19, 2023 | finance.yahoo.comIstaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024December 18, 2023 | finance.yahoo.comWindtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNovember 16, 2023 | finance.yahoo.comWindtree Therapeutics Announces Issuance of New Pure SERCA2a Activator PatentNovember 9, 2023 | msn.comWindtree TherapeuticS GAAP EPS of -$0.86November 9, 2023 | finance.yahoo.comWindtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business UpdatesNovember 8, 2023 | finance.yahoo.comWindtree to Present at the Sidoti Micro Cap Conference on November 16thOctober 12, 2023 | tmcnet.comWindtree to Present at the ThinkEquity Conference on October 19th in New York CityOctober 12, 2023 | finance.yahoo.comWindtree to Present at the ThinkEquity Conference on October 19th in New York CityOctober 10, 2023 | finance.yahoo.comWindtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17thOctober 3, 2023 | finance.yahoo.comWindtree to Present at the Dawson James Small Cap Growth Conference on October 12th Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here WINT Media Mentions By Week WINT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. WINT News Sentiment▼0.490.62▲Average Medical News Sentiment WINT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. WINT Articles This Week▼81▲WINT Articles Average Week Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TCBP News Today BCDA News Today SRNE News Today FRTX News Today ALBT News Today CELZ News Today TTNP News Today PALI News Today GENE News Today KRBP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:WINT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.